Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis

Abstract

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) provided funding for this study. Yu and Devercelli are currently salaried employees of BIPI. Wu, Chuang, Wang, Pan, and Benjamin are currently employees of Evidera, which provides consulting and other research services to pharmaceutical, device, government, and nongovernment organizations. In their salaried positions, they work with a variety of companies and organizations and are precluded from receiving payment or honoraria directly from these organizations for services rendered. Evidera received funding from BIPI to conduct the analysis. Coultas was previously a paid consultant of BIPI. The contents do not represent the views of the Department of Veterans Affairs or the U.S. government. This manuscript does not contain clinical studies or patient data. The authors have full control of all primary data, and they agree to allow the journal to review their data if requested. All authors meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors, and they are fully responsible for all content and editorial decisions and were involved at all stages of manuscript development. The manuscript was drafted by Benjamin, Wu, and Yu and revised by Wang, Pan, Yu, Coultas, and Devercelli. The study was designed by Yu, Wu, Chuang, Wang, Benjamin, and Coultas. Statistical analysis was conducted by Wu, Chuang, and Wang. Senior review was provided by Coultas and Devercelli.

Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden

“…The overall economic and health care burden of IPF is well-recognized [23–27]. This study uniquely highlights the burden associated with MV use in IPF, while reinforcing with nationwide data the poor outcomes reported in prior smaller studies.…”

Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases

“…Based on the results of the epidemiological studies, a signi cant proportion of hospitalizations in ILD patients were related to ILD or other reasons causing respiratory symptoms [1][2][3][4], and the majority of ILD patients had experienced some kind of event requiring hospitalization during their disease history [4]. Most of the register-based studies have investigated solely patients with IPF, while those of other ILDs are sparse.…”

“…One substantial problem in AE-ILD research is the fact that no speci c diagnosis code exists for AE-ILD. As a consequence, the large epidemiological studies mentioned above do not provide detailed information on the number of AE-ILDs [1][2][3][4]. In other studies with access to the patient data, the proportion of AE-ILDs out of all the hospitalizations caused by an acute respiratory deterioration has ranged between 29-55% [5,6,10,11], when only two of these investigations included patients with non-IPF ILDs [5,11].…”

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use

“…Several recent studies suggested that IPF incurred a substantial economic and health burden [18][19][20][21][22][23]. The methods varied between studies from an Adelphi panel [22], database analyses of patients with IPF [20,21] and comparisons of IPF and non-IPF estimates [18,19,23].…”

“…The methods varied between studies from an Adelphi panel [22], database analyses of patients with IPF [20,21] and comparisons of IPF and non-IPF estimates [18,19,23]. The latter provide useful information on the relative cost burden of IPF from a US-payer perspective, and both studies agreed on a more than twofold increase in the annual rate of hospitalisation (post-index) [18,19,23]. Raimundo et al [20] estimated that respiratory events were responsible for half of the hospitalisations that occurred during the 3 years of observations for patients with IPF.…”